Neuregulin allosteric anti-HER3 antibody

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10196455
APP PUB NO 20160319033A1
SERIAL NO

15035129

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure relates to neuregulin (NRG)-non competitive allosteric anti-human-HER3 antibodies and uses thereof in diagnostic and therapeutic methods.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)75013 PARIS
UNIVERSITÉ DE MONTPELLIER34090 MONTPELLIER
INSTITUT REGIONAL DU CANCER DE MONTPELLIER208 RUE DES APOTHICAIRES F-34090 MONTPELLIER F-34090

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chardes, Thierry Montpellier, FR 11 52
Gaborit, Nadege Rehovot, IL 2 9
Larbouret, Christel Montpellier, FR 11 61
Pelegrin, Andre Montpellier, FR 15 73

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Aug 5, 2026
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 5, 2030
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00